Citations (37)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (2)
Ibrahim Gueler, Susanne Mueller, Matthias Helmschrott, Christian U Oeing, Christian Erbel, Lutz Frankenstein, Christian Gleißner, Arjang Ruhparwar, Philipp Ehlermann, Thomas J Dengler, Hugo A Katus & Andreas O Doesch. (2013) Effects of vildagliptin (Galvus®) therapy in patients with type 2 diabetes mellitus after heart transplantation. Drug Design, Development and Therapy 7, pages 297-303.
Read now
Read now
Amit S Kalgutkar & Deepak K Dalvie. (2012) Drug discovery for a new generation of covalent drugs. Expert Opinion on Drug Discovery 7:7, pages 561-581.
Read now
Read now
Articles from other publishers (35)
GR Sridhar, Kaushik Pandit, Sona Warrier & Ashish Birla. (2023) Sustained-Release Vildagliptin 100 mg in Type 2 Diabetes Mellitus: A Review. Cureus.
Crossref
Crossref
Siva Prasad Panda. (2023) Role of DPP4 and DPP4i in Glucose Homeostasis and Cardiorenal Syndrome. Endocrine, Metabolic & Immune Disorders - Drug Targets 23:2, pages 179-187.
Crossref
Crossref
Katherine O. Kopp, Elliot J. Glotfelty, Yazhou Li & Nigel H. Greig. (2022) Glucagon-like peptide-1 (GLP-1) receptor agonists and neuroinflammation: Implications for neurodegenerative disease treatment. Pharmacological Research 186, pages 106550.
Crossref
Crossref
Gadde Sathish Kumar, Prashant S. Shinde, Haifeng Chen, Krishnamoorthy Muralirajan, Rajesh Kancherla & Magnus Rueping. (2022) Paired Electrolysis for Decarboxylative Cyanation: 4-CN-Pyridine, a Versatile Nitrile Source. Organic Letters 24:35, pages 6357-6363.
Crossref
Crossref
Sadia Malik, Nida Zaidi, Mohammad Khursheed Siddiqi, Nabeela Majid, Aiman Masroor, Samreen Salam & Rizwan H. Khan. (2022) Mechanistic insight into inhibition of amyloid fibrillation of human serum albumin by Vildagliptin. Colloids and Surfaces B: Biointerfaces 216, pages 112563.
Crossref
Crossref
Mahaveer Sharma & S. S. Agrawal. (2021) Bioequivalence study of different brands of vildagliptin in healthy human subjects. Future Journal of Pharmaceutical Sciences 7:1.
Crossref
Crossref
Basak Turk‐Erbul, Ecem F. Karaman, Gizem N. Duran, Mehmet Ozbil, Sibel Ozden & Fusun Goktas. (2021) Synthesis, in vitro cytotoxic and apoptotic effects, and molecular docking study of novel adamantane derivatives. Archiv der Pharmazie 354:5, pages 2000256.
Crossref
Crossref
Dana Abdelrahim, MoezAlIslam E. Faris, Mohamed Hassanein, Ayman Z. Shakir, Ayesha M. Yusuf, Aljohara S. Almeneessier & Ahmed S. BaHammam. (2021) Impact of Ramadan Diurnal Intermittent Fasting on Hypoglycemic Events in Patients With Type 2 Diabetes: A Systematic Review of Randomized Controlled Trials and Observational Studies. Frontiers in Endocrinology 12.
Crossref
Crossref
Surendra Kumar. (2021) Comparison of safety and efficacy of glimepiride-metformin and vildagliptin- metformin treatment in newly diagnosed type 2 diabetic patients. Indian Journal of Endocrinology and Metabolism 25:4, pages 326.
Crossref
Crossref
Akinsomisoye Olumide Stephen, Owolabi Adegbenga Rotimi, Azeez Taoreed Adegoke & Osuntokun Opeyemi Samson. (2021) Reprotoxic activities of vildagliptin administration in male Wistar rats. Brazilian Journal of Pharmaceutical Sciences 57.
Crossref
Crossref
Päivi Maria Paldánius. (2020) Evaluating the Evidence behind the Novel Strategy of Early Combination from Vision to Implementation. Diabetes & Metabolism Journal 44:6, pages 785-801.
Crossref
Crossref
David Matthews, Stefano Del Prato, Viswanathan Mohan, Chantal Mathieu, Sergio Vencio, Juliana C. N. Chan, Michael Stumvoll & Päivi Maria Paldánius. (2020) Insights from VERIFY: Early Combination Therapy Provides Better Glycaemic Durability Than a Stepwise Approach in Newly Diagnosed Type 2 Diabetes. Diabetes Therapy 11:11, pages 2465-2476.
Crossref
Crossref
Malgorzata Sztiller-Sikorska & Malgorzata Czyz. (2020) Parthenolide as Cooperating Agent for Anti-Cancer Treatment of Various Malignancies. Pharmaceuticals 13:8, pages 194.
Crossref
Crossref
Noha H. Sayed, Nevine Fathy, Mona A. Kortam, Mostafa A. Rabie, Ahmed F. Mohamed & Ahmed S. Kamel. (2019) Vildagliptin Attenuates Huntington’s Disease through Activation of GLP-1 Receptor/PI3K/Akt/BDNF Pathway in 3-Nitropropionic Acid Rat Model. Neurotherapeutics 17:1, pages 252-268.
Crossref
Crossref
Yulong Chen, Quanmin Li, Ying Han, Hongmei Ji, Mingjun Gu, Rongwen Bian, Weiguang Ding, Jian Cheng & Yiming Mu. (2019) Vildagliptin Versus α-Glucosidase Inhibitor as Add-On to Metformin for Type 2 Diabetes: Subgroup Analysis of the China Prospective Diabetes Study. Diabetes Therapy 11:1, pages 247-257.
Crossref
Crossref
Eva Rahman Kabir, Mohammad Kawsar Sharif Siam & Nashrah Mustafa. (2019)
Scaffold of
N
-(2-(2-(tosylcarbamoyl)hydrazinyl)ethyl)isonicotinamidereveals anticancer effects through selective inhibition of FAP
.
Scaffold of
N
-(2-(2-(tosylcarbamoyl)hydrazinyl)ethyl)isonicotinamidereveals anticancer effects through selective inhibition of FAP
.
Avinash MishraMegan CrossAndreas HofmannMark J. CosterAbdul KarimAbdul Sattar. (2019) Identification of a Novel Scaffold for Inhibition of Dipeptidyl Peptidase-4. Journal of Computational Biology 26:12, pages 1470-1486.
Crossref
Crossref
Kristine Senkane, Ekaterina V. Vinogradova, Radu M. Suciu, Vincent M. Crowley, Balyn W. Zaro, J. Michael Bradshaw, Ken A. Brameld & Benjamin F. Cravatt. (2019) The Proteome‐Wide Potential for Reversible Covalency at Cysteine. Angewandte Chemie International Edition 58:33, pages 11385-11389.
Crossref
Crossref
Kristine Senkane, Ekaterina V. Vinogradova, Radu M. Suciu, Vincent M. Crowley, Balyn W. Zaro, J. Michael Bradshaw, Ken A. Brameld & Benjamin F. Cravatt. (2019) The Proteome‐Wide Potential for Reversible Covalency at Cysteine. Angewandte Chemie.
Crossref
Crossref
Mi Seon Seo, Hongliang Li, Jin Ryeol An, In Duk Jung, Won-Kyo Jung, Kwon-Soo Ha, Eun-Taek Han, Seok-Ho Hong, Il-Whan Choi & Won Sun Park. (2018) Vildagliptin, an Anti-diabetic Drug of the DPP-4 Inhibitor, Induces Vasodilation via Kv Channel and SERCA Pump Activation in Aortic Smooth Muscle. Cardiovascular Toxicology 19:3, pages 244-254.
Crossref
Crossref
Samar S. Khalaf, Mohamed M. Hafez, Eman T. Mehanna, Noha M. Mesbah & Dina M. Abo-Elmatty. (2019) Combined vildagliptin and memantine treatment downregulates expression of amyloid precursor protein, and total and phosphorylated tau in a rat model of combined Alzheimer’s disease and type 2 diabetes. Naunyn-Schmiedeberg's Archives of Pharmacology 392:6, pages 685-695.
Crossref
Crossref
Mohamed M. El-Wekil, Khaled K. Abdelhady, Randa A. Abdel Salam & Ghada M. Hadad. (2019) Applications of Fourier transform infrared spectroscopic method for simultaneous quantitation of some hypoglycemic drugs in their binary mixtures. Spectrochimica Acta Part A: Molecular and Biomolecular Spectroscopy 213, pages 249-253.
Crossref
Crossref
Cyrus V. Desouza, Namita Gupta & Anery Patel. (2015) Cardiometabolic Effects of a New Class of Antidiabetic Agents. Clinical Therapeutics 37:6, pages 1178-1194.
Crossref
Crossref
Muhammad Abdul-Ghani, Ralph A. DeFronzo & Roy Eldor. 2015. International Textbook of Diabetes Mellitus. International Textbook of Diabetes Mellitus
686
708
.
D. Allan Butterfield, Fabio Di Domenico & Eugenio Barone. (2014) Elevated risk of type 2 diabetes for development of Alzheimer disease: A key role for oxidative stress in brain. Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease 1842:9, pages 1693-1706.
Crossref
Crossref
Stalin Selvaraj, Sridharan Krishnaswamy, Venkappayya Devashya, Swaminathan Sethuraman & Uma Maheswari Krishnan. (2014) Flavonoid-Metal Ion Complexes: A Novel Class of Therapeutic Agents. Medicinal Research Reviews 34:4, pages 677-702.
Crossref
Crossref
Anna Berteotti, Federica Vacondio, Alessio Lodola, Michele Bassi, Claudia Silva, Marco Mor & Andrea Cavalli. (2014) Predicting the Reactivity of Nitrile-Carrying Compounds with Cysteine: A Combined Computational and Experimental Study. ACS Medicinal Chemistry Letters 5:5, pages 501-505.
Crossref
Crossref
Jayasankar Kosaraju, Vishakantha Murthy, Rizwan Basha Khatwal, Anil Dubala, Santhivardhan Chinni, Satish Kumar Muthureddy Nataraj & Duraiswamy Basavan. (2013) Vildagliptin: an anti-diabetes agent ameliorates cognitive deficits and pathology observed in streptozotocin-induced Alzheimer's disease. Journal of Pharmacy and Pharmacology 65:12, pages 1773-1784.
Crossref
Crossref
Ralph A. DeFronzo, Roy Eldor & Muhammad Abdul-Ghani. (2013) Pathophysiologic Approach to Therapy in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes Care 36:Supplement_2, pages S127-S138.
Crossref
Crossref
Amit S. Kalgutkar, Deepak Dalvie, R. Scott Obach & Dennis A. Smith. 2012. Reactive Drug Metabolites. Reactive Drug Metabolites
313
334
.
Paresh Ved & Samrat Shah. (2012) Evaluation of vildagliptin and fixed dose combination of vildagliptin and metformin on glycemic control and insulin dose over 3 months in patients with type 2 diabetes mellitus. Indian Journal of Endocrinology and Metabolism 16:7, pages 110.
Crossref
Crossref
Claire H. Wilson & Catherine A. Abbott. 2011. Proteinases as Drug Targets. Proteinases as Drug Targets
1
43
.
Michael Haidinger, Johannes Werzowa, Hans-Christian Voigt, Johannes Pleiner, Gunar Stemer, Manfred Hecking, Dominik Döller, Walter H Hörl, Thomas Weichhart & Marcus D Säemann. (2010) A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation. Trials 11:1.
Crossref
Crossref
Fraser F. Fleming, Lihua Yao, P. C. Ravikumar, Lee Funk & Brian C. Shook. (2010) Nitrile-Containing Pharmaceuticals: Efficacious Roles of the Nitrile Pharmacophore. Journal of Medicinal Chemistry 53:22, pages 7902-7917.
Crossref
Crossref
Abd A. Tahrani, Milan K. Piya, Amy Kennedy & Anthony H. Barnett. (2010) Glycaemic control in type 2 diabetes: Targets and new therapies. Pharmacology & Therapeutics 125:2, pages 328-361.
Crossref
Crossref